Financials in USD. Standardized financial statements.
A compact view of how Cumberland Pharmaceuticals Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $44.52M | $37.87M | $39.55M | $42.01M | $35.99M | $37.44M | $34.39M | $40.74M | $41.15M | $33.03M |
| Revenue Growth? | +17.6% | -4.3% | -5.9% | +16.7% | -3.9% | +8.9% | -15.6% | -1.0% | +24.6% | 0.0% |
| Cost of Revenue? | $6.67M | $6.59M | $6.07M | $9.12M | $8.81M | $8.65M | $7.42M | $7.38M | $7.37M | $5.96M |
| Gross Profit? | $37.85M | $31.28M | $33.49M | $32.89M | $27.17M | $28.79M | $26.97M | $33.36M | $33.78M | $27.07M |
| Gross Margin? | +85.0% | +82.6% | +84.7% | +78.3% | +75.5% | +76.9% | +78.4% | +81.9% | +82.1% | +82.0% |
| Operating Expenses? | $40.65M | $37.71M | $43.04M | $38.60M | $34.85M | $35.17M | $36.26M | $40.75M | $37.86M | $28.50M |
| Operating Income? | -$2.79M | -$6.43M | -$9.55M | -$5.70M | -$7.68M | -$6.38M | -$9.29M | -$7.39M | -$4.08M | -$1.43M |
| EBITDA? | $2.49M | $182,422 | $2.49M | $332,919 | -$857,833 | -$1.56M | -$4.64M | -$8.19M | -$1.13M | $1.17M |
| Income Before Tax | -$2.82M | -$6.47M | -$6.28M | -$5.58M | -$5.56M | -$6.57M | -$9.29M | -$7.02M | -$3.87M | -$1.33M |
| Income Tax Expense | $40,256 | -$22,669 | $45,769 | $68,850 | $34,891 | $55,902 | -$79,316 | $16,636 | $4.17M | -$330,924 |
| Net Income? | -$2.84M | -$6.48M | -$6.28M | -$5.57M | -$3.51M | -$3.34M | -$3.54M | -$6.96M | -$7.98M | -$944,683 |
| EPS? | $-0.19 | $-0.46 | $-0.44 | $-0.38 | $-0.24 | $-0.22 | $-0.23 | $-0.45 | $-0.50 | $-0.06 |
| Diluted EPS? | $-0.19 | $-0.46 | $-0.44 | $-0.38 | $-0.24 | $-0.22 | $-0.23 | $-0.45 | $-0.50 | $-0.06 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality